- October 27, 2025
Ailux Announces Posters at American College of Rheumatology (ACR) Convergence 2025
SHANGHAI (CHINA) and SOMERVILLE, MA (US) — October 27, 2025 — Ailux, an innovator in AI-powered biologics and a subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced scientific presentations at the ACR Convergence 2025.
Ailux leveraged an AI-powered antibody discovery platform to precisely design two therapeutic candidates with desired properties for the treatment of inflammatory or autoimmune diseases.
“Our first-in-class FcRn × albumin bispecific antibody combines potent FcRn blockade with extended half-life, offering a long-acting treatment that could transform the patient journey with autoantibody diseases,” said Alex Li, CEO of Ailux. “Our half-life extended TL1A antibody shows potent anti-inflammatory activity and reduced immunogenicity risk with a unique mechanism of action, demonstrating its potential as a safer, more durable therapy, and as a promising backbone in next-generation multispecifics.”
The posters will be available for viewing during the ACR Convergence 2025, with the below details:
Full poster session details can be accessed via the ACR program.
About Ailux
Ailux is a biologics innovation company dedicated to developing advanced biotherapeutics with AI-powered solutions. As XtalPi’s dedicated biologics platform, Ailux integrates proprietary computational models with state-of-the-art wet lab capabilities to tackle previously undruggable targets and design molecules with novel therapeutic profiles. With a global team of more than 100 members, Ailux partners with leading biopharmaceutical companies to translate cutting-edge science into transformative medicines.
For more information, visit ailuxbio.com.
To learn more about collaboration and partnerships, contact bd@ailuxbio.com.